<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitals-Reference-Cited by-同舟云学术

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Published:2024-01-30 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Iovleva Alina¹,McElheny Christi L.¹,Fowler Erin L.¹,Cober Eric²,Herc Erica S.³,Arias Cesar A.⁴⁵⁶^ORCID,Hill Carol⁷^ORCID,Baum Keri⁷,Fowler, Jr. Vance G.⁷⁸,Chambers Henry F.⁹,Greenwood-Quaintance Kerryl E.¹⁰,Patel Robin¹⁰¹¹^ORCID,van Duin David¹²^ORCID,Bonomo Robert A.¹³¹⁴¹⁵¹⁶¹⁷^ORCID,Doi Yohei¹¹⁸¹⁹^ORCID

Affiliation:

1. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

2. Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA

3. Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA

4. Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA

5. Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA

6. Department of Medicine, Weill Cornell Medical College, New York, New York, USA

7. Duke Clinical Research Institute, Durham, North Carolina, USA

8. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA

9. Division of Infectious Diseases, University of California San Francisco School of Medicine, San Francisco, California, USA

10. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

11. Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

12. Division of Infectious Diseases University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

13. Department of Medicine, Division of Infectious Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

14. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

15. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

16. CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA

17. Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

18. Departments of Microbiology and Infectious Diseases, Fujita Health University, Toyoake, Japan

19. Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Abstract

ABSTRACT The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC 50 /MIC 90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01258-23

Reference9 articles.

1. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter Baumannii Among Patients From Different Global Regions

2. Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

3. Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

4. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

5. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii